

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 December 2024 (12.12.2024)



(10) International Publication Number
WO 2024/253833 A3

(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/505 (2006.01)
A61K 31/415 (2006.01) A61K 31/33 (2006.01)
A61K 31/166 (2006.01)

(21) International Application Number:

PCT/US2024/030335

(22) International Filing Date:

21 May 2024 (21.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/506,265 05 June 2023 (05.06.2023) US
63/603,280 28 November 2023 (28.11.2023) US
63/574,382 04 April 2024 (04.04.2024) US

(71) Applicant: **PRIOVANT THERAPEUTICS, INC.**
[US/US]; 1007 Slater Road, Suite 250, Durham, North Carolina 27703 (US).

(72) Inventors: **JOHNSON, Brendan**; c/o Pfizer Inc., 66 Hudson Boulevard East, New York, New York 10001-2192 (US). **MUDD, Paul N.**; c/o Pfizer Inc., 66 Hudson Boulevard East, New York, New York 10001-2192 (US). **FRANCO, Matthew Anthony**; c/o Pfizer Inc., 66 Hudson Boulevard East, New York, New York 10001-2192 (US). **KHETARPAL, Nikhil**; c/o Pfizer Inc., 66 Hudson Boulevard East, New York, New York 10001-2192 (US).

(74) Agent: **MUELLER, Lisa**; Casimir Jones SC, 2275 Deming Way, Suite # 300, Middleton, Wisconsin 53562 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(88) Date of publication of the international search report:

23 January 2025 (23.01.2025)

(54) Title: METHODS FOR TREATING DERMATOMYOSITIS WITH BREPOCITINIB




FIG. 1

(57) Abstract: The present disclosure provides methods related to treatment of a chronic immune-mediated disease of the skin and muscles. In particular, the present disclosure provides methods for the oral administration of a JAK inhibitor, or a pharmaceutically acceptable salt thereof for the treatment of dermatomyositis.

WO 2024/253833 A3